Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.

Launched by PROF. DR. CEMIL TASCIOGLU EDUCATION AND RESEARCH HOSPITAL ORGANIZATION · Nov 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two treatments—transcutaneous tibial nerve stimulation (TTNS) and parasacral nerve stimulation (PSS)—to help women with Multiple Sclerosis (MS) who have symptoms of an overactive bladder. These symptoms can include needing to urinate frequently, a strong urge to urinate, and leakage of urine. The goal is to see if these treatments can improve how often participants have to go to the bathroom, how much they can hold, and their overall quality of life related to bladder issues.

To participate in this study, women must be over 18 years old and have specific symptoms related to their overactive bladder. They should also have stable MS, meaning they haven’t had any significant flare-ups in the last month. Some individuals may not qualify, such as those with urinary tract infections, certain other health conditions, or who are pregnant. If eligible, participants can expect to receive one of the two treatment methods and will be monitored for changes in their symptoms and quality of life. This research is currently recruiting participants, and it offers a chance to contribute to understanding better ways to manage bladder symptoms in women with MS.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Having symptoms related to overactive bladder (OAB-v8 score ⩾8),
• • Over 18 years of age
• • No relapse for at least 1 month
• • All types of MS, including those with relapses
• • Female MS patients with an Expanded Disability Status Scale (EDSS) score below 7.0
• • Agreeing to participate in the research
• Exclusion Criteria:
• • Patients with urinary tract infections
• • Patients diagnosed with diabetes mellitus
• • Patients using diuretic drugs or patients with a clean intermittent catheter
• • Patients with a history of different urological diseases
• • Patients with heart or brain pacemaker users, those with epilepsy, and patients with language and cognitive limitations
• • Patients who are pregnant or in the postpartum period
• • Lack of activity performance for 2 weeks (regardless of which group)